

Fahmi, Mochamad ao-2021-013526 - Manuscript Submission to ACS Omega 13-Mar-2021

1 message

ACS Omega <onbehalf@manuscriptcentral.com>

Sat, Mar 13, 2021 at 6:22 PM

Reply-To: support@services.acs.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: yu.yu.aung-2018@fst.unair.ac.id, alfinda-n-k@fst.unair.ac.id, leehweivoon@um.edu.my, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

13-Mar-2021

Journal: ACS Omega

Manuscript ID: ao-2021-013526

Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"

Authors: Aung, Yu Yu; Kristanti, Alfinda Novi; Lee, Hwei V.; Fahmi, Mochamad

Manuscript Status: Submitted

Dear Dr. Fahmi:

Your manuscript has been successfully transferred to ACS Omega.

Please reference the above manuscript ID in all future correspondence. If there are any changes in your contact information, please log in to ACS Paragon Plus with your ACS ID at <http://paragonplus.acs.org/login> and select "Edit Your Profile" to update that information.

You can view the status of your manuscript by selecting the tab labeled "My Authoring Activity" in ACS Paragon Plus after logging in to <http://paragonplus.acs.org/login>.

Journal Publishing Agreement and Copyright

Upon acceptance, ACS Publications will require the corresponding author to sign and submit a Journal Publishing Agreement. This agreement gives authors a number of rights regarding the use of their manuscripts. At acceptance, the corresponding author will receive an email linking through to the Journal Publishing Agreement Wizard, which helps you select the most appropriate license for your manuscript.

For more information please see: https://pubs.acs.org/page/copyright/journals/jpa_faqs.html

ACS Authoring Services

Did you know that ACS provides authoring services to help scientists prepare their manuscripts and communicate their research more effectively? Trained chemists with field-specific expertise are available to edit your manuscript for grammar, spelling, and other language errors, and our figure services can help you increase the visual impact of your research.

Visit <https://authoringservices.acs.org> to see how we can help you! Please note that the use of these services does not guarantee that your manuscript will be accepted for publication.

Thank you for submitting your manuscript to ACS Omega.

Sincerely,

Dr. Krishna Ganesh and Dr. Deqing Zhang
ACS Omega

PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at Pubsupdates@acs.org if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

Fahmi, Mochamad ao-2021-013526.R1 - Manuscript Revision Request 06-May-2021

2 messages

ACS Omega <onbehalf@manuscriptcentral.com>
Reply-To: Zhang-office@omega.acs.org
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Thu, May 6, 2021 at 1:18 PM

06-May-2021

Journal: ACS Omega
Manuscript ID: ao-2021-013526.R1
Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"
Author(s): Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

COVID-19 Support: Please visit the following website to access important information for ACS authors and reviewers during the COVID-19 crisis: <https://axial.acs.org/2020/03/25/chemists-covid-19-coronavirus/>

We are flexible in these unprecedented times affecting the global research community. If you need more time to complete authoring or reviewing tasks, please contact the editorial office and request an extension.

Dear Dr. Fahmi:

Thank you for submitting your manuscript to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopencience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

"Boronic Acid-Modified Nanomaterials for Biomedical Applications" has been examined by expert reviewers. In its current form, your manuscript is not suitable for publication in ACS Omega. The reviewers have raised points that require significant consideration. However, with an adequate point-by-point response and the appropriate revisions, your paper may become acceptable for publication.

We would like to receive your revision no later than 27-May-2021. The revision should address the reviewers' comments and include a point-by-point response. Your manuscript will be subject to further peer review.

Please note that you will receive a follow-up message within 24 hours describing the non-scientific changes you must make to your manuscript before you submit the revision.

To revise your manuscript, log into ACS Paragon Plus with your ACS ID at <http://paragonplus.acs.org/login> and select "My Authoring Activity". There you will find your manuscript title listed under "Revisions Requested by Editorial Office." Your original files are available to you when you upload your revised manuscript. If you are replacing files, please remove the old version of the file from the manuscript before uploading the new file.

When submitting your revised manuscript through ACS Paragon Plus, you will be able to respond to the comments made by the reviewer(s) in the text box provided or by attaching a file containing your detailed responses to all of the points raised by the reviewers.

Please upload manuscript file that is free of any annotations or highlights.

Funding Sources: Authors are required to report ALL funding sources and grant/award numbers relevant to this manuscript. Enter all sources of funding for ALL authors relevant to this manuscript in BOTH the Open Funder Registry tool in ACS Paragon Plus and in the manuscript to meet this requirement. See http://pubs.acs.org/page/4authors/funder_options.html for complete instructions.

ORCID: Authors submitting manuscript revisions are required to provide their own validated ORCID iDs before

completing the submission, if an ORCID iD is not already associated with their ACS Paragon Plus user profiles. This iD may be provided during original manuscript submission or when submitting the manuscript revision. You can provide only your own ORCID iD, a unique researcher identifier. If your ORCID iD is not already validated and associated with your ACS Paragon Plus user profile, you may do so by following the ORCID-related links in the Email/Name section of your ACS Paragon Plus account. All authors are encouraged to register for and associate their own ORCID iDs with their ACS Paragon Plus profiles. The ORCID iD will be displayed in the published article for any author on a manuscript who has a validated ORCID iD associated with ACS Paragon Plus when the manuscript is accepted. Learn more at <http://www.orcid.org>.

In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses Crossref Similarity Check Powered by iThenticate to screen submitted manuscripts for similarity to published material, and other software to screen previous submissions to ACS journals. Note that your manuscript may be screened during the submission process.

We look forward to seeing your paper in ACS Omega.

Sincerely,

Dr. Deqing Zhang
Coeditor
ACS Omega
Phone: +86-10-62639355
Fax: (202) 559-0879
Email: Zhang-office@omega.acs.org

Reviewer(s)' Comments to Author:

Reviewer: 1

Recommendation: Publish after major revisions.

Comments:

Though part of the maintext was revised according to the suggestions by the revieweres. Still the authors need to well construct the whole manuscript. Inter-connection and interrelated category stardard exsits. Scheme 1 is also need to be revised, where glucose sensor is part of biosensing. Cancer and diagnosis is part of biomedical applications.

Additional Questions:

Is the technical quality of the research reported within valid and appropriate?: No

Is this manuscript appealing to a broad audience?: Yes

Are the conclusions adequately supported by the data presented?: Yes

Are the literature references appropriate and up to date?: Yes

Reviewer: 2

Recommendation: Publish as is; no revisions needed.

Comments:

The authors responded to solve all issues raised by the reviewer.
Now, I recommend acceptance of this paper in this journal.

Additional Questions:

Is the technical quality of the research reported within valid and appropriate?: Yes

Is this manuscript appealing to a broad audience?: Yes

Are the conclusions adequately supported by the data presented?: Yes

Are the literature references appropriate and up to date?: Yes

FOR ASSISTANCE WITH YOUR MANUSCRIPT SUBMISSION PLEASE CONTACT:

ACS Publications Customer Services & Information (CSI)

Email: support@services.acs.org

Phone: 202-872-4357

Toll-Free Phone: 800-227-9919 (USA/Canada only)

PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at Pubupdates@acs.org if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

Mochamad Zakki Fahmi <m.zakki.fahmi@fst.unair.ac.id>

Thu, May 6, 2021 at 1:46 PM

To: yu.yu.aung-2018@fst.unair.ac.id

Yu response the 1 comment of reviewer for your last paper

Best Regards,

Mochamad Zakki Fahmi, Ph.D (張家其)
Associate Professor, Department of Chemistry
Universitas Airlangga
Phone : +62-838-32901697
Email : m.zakki.fahmi@fst.unair.ac.id



[Quoted text hidden]

Fahmi, Mochamad ao-2021-013526.R1 - Revised Manuscript Submission to ACS Omega 24-Apr-2021

1 message

ACS Omega <onbehalf@manuscriptcentral.com>

Sat, Apr 24, 2021 at 3:09 PM

Reply-To: support@services.acs.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: yu.yu.aung-2018@fst.unair.ac.id, alfinda-n-k@fst.unair.ac.id, leehweivoon@um.edu.my, m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

24-Apr-2021

Journal: ACS Omega

Manuscript ID: ao-2021-013526.R1

Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"

Authors: Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

Manuscript Status: Submitted

Dear Dr. Fahmi:

Your manuscript has been successfully submitted to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopenscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

Please reference the above manuscript ID in all future correspondence. If there are any changes in your contact information, please log in to ACS Paragon Plus with your ACS ID at <http://paragonplus.acs.org/login> and select "Edit Your Profile" to update that information.

You can view the status of your manuscript by checking your "Authoring Activity" tab on ACS Paragon Plus after logging in to <http://paragonplus.acs.org/login>.

ACS Authoring Services

Did you know that ACS provides authoring services to help scientists prepare their manuscripts and communicate their research more effectively? Trained chemists with field-specific expertise are available to edit your manuscript for grammar, spelling, and other language errors, and our figure services can help you increase the visual impact of your research.

Visit <https://authoringservices.acs.org> to see how we can help you! Please note that the use of these services does not guarantee that your manuscript will be accepted for publication.

Thank you for submitting your manuscript to ACS Omega.

Sincerely,

Dr. Krishna Ganesh and Dr. Deqing Zhang
ACS Omega

PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it

to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at Pubupdates@acs.org if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

Fahmi, Mochamad ao-2021-013526 - Manuscript Revision Request 07-Apr-2021

2 messages

ACS Omega <onbehalf@manuscriptcentral.com>
Reply-To: Zhang-office@omega.acs.org
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Wed, Apr 7, 2021 at 12:53 PM

07-Apr-2021

Journal: ACS Omega
Manuscript ID: ao-2021-013526
Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"
Author(s): Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad

COVID-19 Support: Please visit the following website to access important information for ACS authors and reviewers during the COVID-19 crisis: <https://axial.acs.org/2020/03/25/chemists-covid-19-coronavirus/>

We are flexible in these unprecedented times affecting the global research community. If you need more time to complete authoring or reviewing tasks, please contact the editorial office and request an extension.

Dear Dr. Fahmi:

Thank you for submitting your manuscript to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopencience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

"Boronic Acid-Modified Nanomaterials for Biomedical Applications" has been examined by expert reviewers. In its current form, your manuscript is not suitable for publication in ACS Omega. The reviewers have raised points that require significant consideration. However, with an adequate point-by-point response and the appropriate revisions, your paper may become acceptable for publication.

We would like to receive your revision no later than 28-Apr-2021. The revision should address the reviewers' comments and include a point-by-point response. Your manuscript will be subject to further peer review.

Please note that you will receive a follow-up message within 24 hours describing the non-scientific changes you must make to your manuscript before you submit the revision.

To revise your manuscript, log into ACS Paragon Plus with your ACS ID at <http://paragonplus.acs.org/login> and select "My Authoring Activity". There you will find your manuscript title listed under "Revisions Requested by Editorial Office." Your original files are available to you when you upload your revised manuscript. If you are replacing files, please remove the old version of the file from the manuscript before uploading the new file.

When submitting your revised manuscript through ACS Paragon Plus, you will be able to respond to the comments made by the reviewer(s) in the text box provided or by attaching a file containing your detailed responses to all of the points raised by the reviewers.

Please upload manuscript file that is free of any annotations or highlights.

Funding Sources: Authors are required to report ALL funding sources and grant/award numbers relevant to this manuscript. Enter all sources of funding for ALL authors relevant to this manuscript in BOTH the Open Funder Registry tool in ACS Paragon Plus and in the manuscript to meet this requirement. See http://pubs.acs.org/page/4authors/funder_options.html for complete instructions.

ORCID: Authors submitting manuscript revisions are required to provide their own validated ORCID iDs before

completing the submission, if an ORCID iD is not already associated with their ACS Paragon Plus user profiles. This iD may be provided during original manuscript submission or when submitting the manuscript revision. You can provide only your own ORCID iD, a unique researcher identifier. If your ORCID iD is not already validated and associated with your ACS Paragon Plus user profile, you may do so by following the ORCID-related links in the Email/Name section of your ACS Paragon Plus account. All authors are encouraged to register for and associate their own ORCID iDs with their ACS Paragon Plus profiles. The ORCID iD will be displayed in the published article for any author on a manuscript who has a validated ORCID iD associated with ACS Paragon Plus when the manuscript is accepted. Learn more at <http://www.orcid.org>.

In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses Crossref Similarity Check Powered by iThenticate to screen submitted manuscripts for similarity to published material, and other software to screen previous submissions to ACS journals. Note that your manuscript may be screened during the submission process.

We look forward to seeing your paper in ACS Omega.

Sincerely,

Dr. Deqing Zhang
Coeditor
ACS Omega
Phone: +86-10-62639355
Fax: (202) 559-0879
Email: Zhang-office@omega.acs.org

Reviewer(s)' Comments to Author:

Reviewer: 1

Recommendation: Publish after major revisions.

Comments:

The manuscript summarized boron based nanomaterials and their biomedical application. Boron modified nanomaterials displayed intriguing features, yet, the authors needs to summarize them in a more logical way. A major revision was required before further consideration. Followings are issues that need to be addressed properly.

Q1. The scheme figure is a bit problematic. Glucose sensor is one of the aspect of biosensing. Cancer is a disease and not suitable for representing one of biomedical application of boronic acids. It can be either cancer diagnosis or treatment, rather than simple cancer. Particularly in Section 3, the content needs to be categorized.

Q2. All the format of figure captions shall be consistent. Apparently, the figure caption of Scheme 3 is different with others.

Q3. Some of the statements is verbose. The authors need to summarize the progress of boronic acid based nanomaterials. For example, in section 3.3, some of the content needs to combined together as boronic acid based nanomaterial for fluorescent sensors.

Q4. The knowledge of boron including its Lewis acidity have been extensively reviewed in the past decades. The authors should put emphasis on the unique features of boron based nanomaterials. Thus, Section 1 could be more concise.

Q5. For Section 2.1, I suggest more discussion shall be focused on the current methods for preparing boron modified nanoparticles and summarized the effect of the different doping on the properties of nanomaterials.

Q6. Section 5.1 seems to focus on boronic acid modified polymer, which may be not related to the topic of boron modified nanomaterials.

Additional Questions:

Is the technical quality of the research reported within valid and appropriate?: In Part (Please Elaborate in Your Review)

Is this manuscript appealing to a broad audience?: Yes

Are the conclusions adequately supported by the data presented?: Yes

Are the literature references appropriate and up to date?: Yes

Reviewer: 2

Recommendation: Publish after major revisions.

Comments:

The authors summarized boronic acid-modified nanomaterials for a variety of biomedical applications, such as bioimaging, biosensing, and antiviral effects. There are the following comments in below. The reviewer recommends that the manuscript should be carefully revised and the current version is not suitable for publication.

< Major comments >

1. Introduction: The authors should cite this reference (SH Hong, M Shin et al, Adv. Funct. Mater. 2019, 26) to mention dynamic supramolecular assembly between boronic acid and diol groups. Also, please cite recent reference (Materials Science and Engineering: C, Volume 71, 1 February 2017, Pages 1064-1071).
2. The section 2 is not sufficient. For instance, the authors only explained the section 2.1 of "Boron modified Carbon dots". The authors should add more sections in detail to include the subsections of GQD, CQD and PDs.
3. The section 5 should be reorganized. The authors focused on boronic acid modified nanomaterials in overall manuscript, but the section 5 included general materials like polymers as antiviral agents.

< Minor comments >

4. Please provide full names before using the abbreviation.
5. Page 7, Line 22: Boronic acid analogue with carboxylic acid, which it can serve as proton donor. -> Boronic acid derivatives with carboxylic acid can serve as proton donor.
6. Page 17, Line 22: CD -> Carbon dots
7. There are many typos and grammatical errors. The authors should use language editing services.

Additional Questions:

Is the technical quality of the research reported within valid and appropriate?: Yes

Is this manuscript appealing to a broad audience?: Yes

Are the conclusions adequately supported by the data presented?: Yes

Are the literature references appropriate and up to date?: Yes

Reviewer: 3

Recommendation: Publish after major revisions.

Comments:

One of the biggest issue is that there are inter-connection and the interrelated significance between each the cited articles are not easy to appreciate. This makes the article to be a "fragmented article". I would have to be carefully saying that this could be due to that my expertise on bio-science not deep enough, or that the writing flow is indeed not well constructed. The writing style seems not consistent from paragraph to paragraph.

Additional Questions:

Is the technical quality of the research reported within valid and appropriate?: Yes

Is this manuscript appealing to a broad audience?: Yes

Are the conclusions adequately supported by the data presented?: No

Are the literature references appropriate and up to date?: Yes

FOR ASSISTANCE WITH YOUR MANUSCRIPT SUBMISSION PLEASE CONTACT:
ACS Publications Customer Services & Information (CSI)
Email: support@services.acs.org
Phone: 202-872-4357
Toll-Free Phone: 800-227-9919 (USA/Canada only)

PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at Pubupdates@acs.org if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

Mochamad Zakki Fahmi <m.zakki.fahmi@fst.unair.ac.id>
To: yu yu <yu.yu.aung-2018@fst.unair.ac.id>

Thu, Apr 8, 2021 at 8:01 AM

yu please resposne all comments for your reviewed paper below

[Quoted text hidden]

--

Best Regards,

Mochamad Zakki Fahmi, Ph.D (張家其)
Assistant Professor, Departement of Chemistry
Airlangga University
Phone : +62-838-32901697
Email : m.zakki.fahmi@fst.unair.ac.id

Kind request - Fahmi, Mochamad ao-2021-013526.R5 14-Jun-2021

Deqing Zhang <zhang-office@omega.acs.org>
To: Mochamad Zakki Fahmi <m.zakki.fahmi@fst.unair.ac.id>

Tue, Jun 15, 2021 at 4:11 PM

Dear Dr. Fahmi:

Thank you for your email and the file you have sent us.

Please note that the files have been uploaded to Paragon Plus system on your behalf.

We would kindly ask you to Log in to your ACS Paragon Plus account and go to "Revisions and Resubmissions Received by Editorial Office" queue. Please review the uploaded files carefully and confirm, by simply replying to this email, that the correct versions have been uploaded.

We look forward to your response as soon as possible.

If you need any assistance, please do not hesitate to contact us.

With sincere regards,

Tijana Maljkovic
Peer Review Analyst
ACS Omega

On behalf of,
Dr. Deqing Zhang
Coeditor
ACS Omega
Email: Zhang-office@omega.acs.org

From: Mochamad Zakki Fahmi <m.zakki.fahmi@fst.unair.ac.id>

Sent: Tuesday, June 15, 2021 4:58 PM

[Quoted text hidden]

[Quoted text hidden]

Fahmi, Mochamad ao-2021-013526.R5 - Manuscript Accepted 15-Jun-2021

1 message

ACS Omega <onbehalf@manuscriptcentral.com>
Reply-To: Zhang-office@omega.acs.org
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Tue, Jun 15, 2021 at 4:37 PM

15-Jun-2021

Journal: ACS Omega
Manuscript ID: ao-2021-013526.R5
Title: "Boronic Acid-Modified Nanomaterials for Biomedical Applications"
Author(s): Aung, Yu-Yu; Kristanti, Alfinda Novi; Lee, Hwei Voon; Fahmi, Mochamad
Manuscript Status: Accept

Dear Dr. Fahmi:

We are pleased to inform you that your manuscript has been accepted for publication in ACS Omega.

You will soon receive an email invitation from the ACS Journal Publishing Staff that contains a link to the online Journal Publishing Agreement. Please sign and submit the journal publishing agreement within 48 hours.

You will be contacted in approximately a week by the ACS Journal Publishing Staff regarding the proofs for your manuscript. Although production of your manuscript will start immediately, your manuscript will not be published until you pay the Article Publishing Charges, <https://acsopencscience.org/open-access/pricing/>. You may qualify for discounts. You will also be contacted shortly with information on how to pay your publishing charges. Article Publishing Charges are waived for invited Editorials and Perspectives.

After you submit corrections for your proofs and pay the article publishing charges, your manuscript will be published on the Web in approximately 48 hours. In view of this fast publication time, it is important to review your proofs carefully. Once a manuscript appears on the Web, it is considered published. Any change to the manuscript once it appears on the Web will need to be submitted to the journal office as a separate Addition & Correction manuscript via the ACS Paragon Plus environment.

Once your paper is published, you can track downloads and citations of your work by logging into the ACS Publishing Center (<https://pubs.acs.org/publish/dashboard>) and selecting "Published."

Sincerely,

Dr. Deqing Zhang
Coeditor
ACS Omega
Phone: +86-10-62639355
Fax: (202) 559-0879
Email: Zhang-office@omega.acs.org

PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at Pubsubupdates@acs.org if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.